All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
On Tuesday 4th June an oral abstract session took place at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. During that session, Abstract 7503 was presented by Nobert Shmitz, University Hospital Münster, Münster, DE, on the final analysis of the AATT study (2007-001052-39), which was conducted by the French Lymphoma Study Association (LYSA) and the German Lymphoma Alliance (GLA). This trial compared the efficacy of allogeneic stem cell transplantation (allo-SCT) to autologous stem cell transplantation (Auto-SCT), as first line consolidation in patients with T-cell lymphomas.
Baseline characteristic |
Auto-SCT cohort |
Allo-SCT cohort |
Total cohort |
---|---|---|---|
Median age (range) |
50 (28–60) |
50 (24–60) |
50 ( 24–60) |
Male patients |
57% |
69% |
63% |
ECOG > 1 |
20% |
20% |
20% |
Disease stage III–IV |
87% |
90% |
88% |
Extranodal disease |
59% |
63% |
61% |
Disease diagnosis: PTCL, not-otherwise specified (NOS)
AITL
ALCL, ALK-negative
Other TCL |
28%
33%
17%
24% |
31%
43%
11%
18% |
29%
38%
14%
21% |
Response
Auto-SCT cohort (n = 54)
Allo-SCT cohort (n = 49)
Total (N = 103)
CR & unconfirmed CR (CRu)
39% (n = 21)
51% (n = 25)
45% (n = 46)
CR/CRu & PD within 2 months
2% (n = 1)
2% (n = 1)
2% (n = 2)
PR
17% (n = 9)
8% (n = 4)
13% (n = 13)
PD
33% (n = 18)
31% (n = 15)
32% (n = 33)
Unknown
6% (n = 3)
0% (n = 0)
3% (n = 3)
Treatment-related death
0% (n = 0)
8% (n = 4)
4% (n =4)
Cause of death
Auto-SCT cohort
(n = 54)
Allo-SCT cohort
(n = 49)
Total cohort
(N = 103)
Lymphoma
24%
22%
22%
Treatment-related mortality (TRM; study treatment only)
0%
16%
21%
TRM (salvage)
7%
4%
14%
Secondary neoplasia
2%
0%
3%
Total
33%
43%
45%
Table 4. Causes of death after SCTCause of death
Auto-SCT cohort
(n = 41)
Allo-SCT cohort
(n = 26)
Total cohort
(n = 58)
Lymphoma (n)
7
1
8
Secondary neoplasia (n)
1
0
1
TRM (study treatment only) (n)
0
8
8
Total (n)
8
9
17
References
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?